Who
David-Alexandre C. Gros
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Eledon Pharmaceuticals; President & COO, Neurocrine Biosciences; SVP, Chief Business Officer, Alnylam Pharmaceuticals.
In numbers
- Trades disclosed
- 23
- Buys
- 4
- Sells
- 0
- Bought
- $121K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 8 Jun 2015
- Last trade
- 31 Jul 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jul 2026filed 4 Aug 2026 | ELDN Eledon PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —354,454 at $0.00 | filing |
| 31 Jul 2026filed 4 Aug 2026 | ELDN Eledon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $658K194,791 at $3.38 | filing |
| 31 Jul 2026filed 4 Aug 2026 | ELDN Eledon PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —354,454 at $0.00 | filing |
| 31 Jul 2026filed 4 Aug 2026 | ELDN Eledon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $658K194,791 at $3.38 | filing |
| 10 Jan 2025filed 13 Jan 2025 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 10 Jan 2025filed 13 Jan 2025 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,500 at $0.00 | filing |
| 21 Nov 2024filed 22 Nov 2024 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,015,743 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —517,454 at $0.00 | filing |
| 1 May 2023filed 2 May 2023 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —383,299 at $0.00 | filing |
| 1 Feb 2023filed 2 Feb 2023 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 1 Feb 2023filed 2 Feb 2023 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —153,600 at $0.00 | filing |
| 1 Feb 2022filed 2 Feb 2022 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —108,000 at $0.00 | filing |
| 20 Dec 2021filed 21 Dec 2021 | ELDN Eledon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $8,9602,000 at $4.48 | filing |
| 17 Aug 2021filed 19 Aug 2021 | ELDN Eledon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $25K4,000 at $6.21 | filing |
| 9 Jun 2021filed 10 Jun 2021 | ELDN Eledon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $24K3,000 at $8.01 | filing |
| 11 Sep 2020filed 15 Sep 2020 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,278.14 at $0.00 | filing |
| 6 Feb 2017filed 8 Feb 2017 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Feb 2017filed 2 Feb 2017 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 20 Dec 2016filed 22 Dec 2016 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 22 Feb 2016filed 24 Feb 2016 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $6,274100 at $62.74 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyALNY · tickerreport.com · 14 Oct 2026Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)ALNY · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name David-Alexandre C. Gros; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.